JL-19001

N/A

Report date: 2026/05/25 20:02:40

Base Information

Drug NameJL-19001
Drug Alias NameJL19001JL-19001
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-15 receptors agonists
TargetsInterleukin-15 receptors
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisUrinary Bladder Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJecho Laboratories Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJecho Biopharmaceuticals Co LtdJecho Laboratories IncJieku (Shanghai) Biomedical Research Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisUrinary Bladder Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A